TNFSF11 and periodontitis: Denosumab effectively inhibits osteoclast activity by targeting the RANKL pathway, but the observed progression of ECR suggests the involvement of alternative, RANKL-independent pathways in odontoclastic resorption, highlighting a need for further research into the mechanisms underlying ECR and the potential side effects of prolonged antiresorptive therapy with denosumab, especially in patients with predisposing factors such as periodontitis.